Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation



Status:Recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/28/2018
Start Date:September 2015
End Date:December 2020
Contact:TG Therapeutics Clinical Support Team
Email:clinicalsupport@tgtxinc.com
Phone:212-554-4484

Use our guide to learn which trials are right for you!

Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)

The purpose of this study is to evaluate the safety and effectiveness of pembrolizumab in
combination with ublituximab and TGR-1202, in patients with advanced CLL or Richter's
Transformation.


Inclusion Criteria:

- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation

- Refractory to or relapsed after at least 1 prior treatment regimen

- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

- Any major surgery, chemotherapy or immunotherapy within the last 14 days

- Known hepatitis B virus, hepatitis C virus or HIV infection

- Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
We found this trial at
3
sites
Seattle, Washington 98109
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
3500 North Broad Street
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials